Emerging therapies in the management of acute ischemic stroke: Innovative approaches and clinical outcomes- A comprehensive literature review

Main Article Content

Arellys Jacqueline Zamora Pachay
Evelyn Viviana Escudero Chávez
William Alexander Cachimuel Carrera
Jessica Viviana Auquillas Cajamarca
Erik Daniel Paredes Morales
Vanessa Victoria Cedeño Arévalo
Ana Belén Urgilés Cabrera

Abstract

Worldwide, acute ischemic stroke continues to be the primary cause of death and disability, requiring ongoing improvements in treatment approaches. With an emphasis on current advancements in collateral evaluation, thrombolytic therapy, endovascular thrombectomy, and neuroprotective treatment, this review examines novel treatments for acute ischemic stroke.


To find relevant research published in the past five years, a thorough search of academic databases was carried out. The inclusion criteria for the inclusion of articles on innovative therapeutics and their implications for managing acute stroke were methodological rigor and direct relevance. With an emphasis on the effectiveness and safety of Tenecteplase, the review emphasizes the crucial role that collateral circulation plays in forecasting patient response to reperfusion treatments and the changing landscape of thrombolytic drugs. Furthermore, the treatment of acute strokes has been transformed by developments in endovascular thrombectomy, which provides better functional results for patients with major artery occlusions. Additionally, neuroprotective drugs have potential as complementary treatments, especially when used in combination with reperfusion procedures. Novel treatments for acute ischemic stroke provide fresh chances to improve patient outcomes and lower stroke-related morbidity and death. To provide equal access to improved stroke care, solve outstanding difficulties, and enhance treatment regimens, further research is required.

Article Details

How to Cite
Zamora Pachay, A. J. ., Escudero Chávez, E. V. ., Cachimuel Carrera, W. A., Auquillas Cajamarca, J. V. ., Paredes Morales, E. D. ., Cedeño Arévalo, V. V., & Urgilés Cabrera, A. B. . (2024). Emerging therapies in the management of acute ischemic stroke: Innovative approaches and clinical outcomes- A comprehensive literature review. International Journal of Medical Science and Clinical Research Studies, 4(03), 581–588. https://doi.org/10.47191/ijmscrs/v4-i03-37
Section
Articles

References

[II] Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update a report from the American Heart Association. Circulation. 2020;141(9):E139–596.

[III] Love BB, Bendixen BH. Classification of subtype of acute ischemic stroke definitions for use in a multicenter clinical trial. Stroke. 1993;24(1):35–41.

[IIII] Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg. 1981;54(6):773–82.

[IIV] Robbins BT, Howington GT, Swafford K, Zummer J, Woolum JA. Advancements in the management of acute ischemic stroke: A narrative review. J Am Coll Emerg Physicians Open [Internet]. 2023 Feb 1 [cited 2024 Mar 25];4(1):e12896. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/emp2.12896

[IV] Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.

[IVI] Liebeskind D, Liaw N. Emerging therapies in acute ischemic stroke. F1000Research [Internet]. 2020 [cited 2024 Mar 25];9. Available from: /pmc/articles/PMC7276937/

[IVII] Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Feb 22;378(8):708–18.

[IVIII] Austein F, Riedel C, Kerby T, Meyne J, Binder A, Lindner T, et al. Comparison of Perfusion CT Software to Predict the Final Infarct Volume after Thrombectomy. Stroke. 2016 Sep 1;47(9):2311–7.

[IIX] Kvistad CE, Næss H, Helleberg BH, Idicula T, Hagberg G, Nordby LM, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol. 2022 Jun 1;21(6):511–9.

[IX] Bivard A, Zhao H, Churilov L, Campbell BCV, Coote S, Yassi N, et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. Lancet Neurol. 2022 Jun 1;21(6):520–7.

[IXI] Menon BK, Buck BH, Singh N, Deschaintre Y, Almekhlafi MA, Coutts SB, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022 Jul 16;400(10347):161–9.

[IXII] Burgos AM, Saver JL. Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials. Stroke. 2019 Aug 1;50(8):2156–62.

[IXIII] Katsanos AH, Safouris A, Sarraj A, Magoufis G, Leker RR, Khatri P, et al. Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis. Stroke. 2021 Jan 1;52(1):308–12.

[IXIV] Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29;384(9958):1929–35.

[IXV] Khatri P, Kleindorfer DO, Devlin T, Sawyer RN, Starr M, Mejilla J, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits the PRISMS randomized clinical trial. JAMA - J Am Med Assoc. 2018 Jul 10;320(2):156–66.

[IXVI] Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. N Engl J Med. 2018 Aug 16;379(7):611–22.

[IXVII] Ma H, Campbell BCV, Parsons MW, Churilov L, Levi CR, Hsu C, et al. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019 May 9;380(19):1795–803.

[IXVIII] Comai A, Haglmüller T, Ferro F, Dall’Ora E, Currò Dossi R, Bonatti G. Sequential endovascular thrombectomy approach (SETA) to acute ischemic stroke: preliminary single-centre results and cost analysis. Radiol Medica. 2015 Jul 17;120(7):655–61.

[IXIX] Turk AS, Siddiqui A, Fifi JT, De Leacy RA, Fiorella DJ, Gu E, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet. 2019 Mar 9;393(10175):998–1008.

[IXX] Kara B, Selcuk HH, Erbahceci Salik A, Zalov H, Yildiz O, Gul G, et al. Single-center experience with the Tigertriever device for the recanalization of large vessel occlusions in acute ischemic stroke. J Neurointerv Surg. 2019 May 1;11(5):455–9.

[IXXI] Chamorro Á, Amaro S, Castellanos M, Gomis M, Urra X, Blasco J, et al. Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy. Int J Stroke. 2017 Jun 1;12(4):377–82.

[IXXII] Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020 Mar 14;395(10227):878–87.

[IXXIII] Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients with Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA - J Am Med Assoc. 2019 Jul 23;322(4):326–35.

[IXXIV] Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet. 2019 Mar 2;393(10174):877–88.

[IXXV] Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 May 1;16(5):360–8.

[IXXVI] Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics’2017 Update: A Report from the American Heart Association. Circulation. 2017 Mar 7;135(10):e146–603.

[IXXVII] Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet. 2016 Aug 20;388(10046):787–96.

[IXXVIII] Saber H, Navi BB, Grotta JC, Kamel H, Bambhroliya A, Vahidy FS, et al. Real-world treatment trends in endovascular stroke therapy. Stroke. 2019 Mar 1;50(3):683–9.

[IXXIX] Patel RAG, McMullen PW. Neuroprotection in the Treatment of Acute Ischemic Stroke. Prog Cardiovasc Dis. 2017 May 1;59(6):542–8.

[IXXX] Stoll G, Schuhmann MK, Kollikowski AM, Pham M. New mechanisms-based therapies in acute ischaemic stroke. Eur Heart J [Internet]. 2024 Jan 9 [cited 2024 Mar 25]; Available from: https://dx.doi.org/10.1093/eurheartj/ehad865